Advertisement

Update in the Investigation of von Willebrand Disease

  • Vishrut K. Srinivasan
  • Jasmina Ahluwalia
Chapter

Abstract

Von Willebrand disease (VWD) is the most common coagulation factor deficiency. The diagnosis of VWD is challenging because of the lack of a single diagnostic test that can be informative about the defects in different parts of the protein. The usual screening tests of coagulation may be normal. If the bleeding history is suggestive and family history for VWD is present, a panel of tests including antigen assay, ristocetin and collagen binding assays and at times multimer analysis may be required. Derived ratios of VWF antigen and activity assays are helpful to ascertain the phenotype of VWD. Most of these tests are available on automated coagulation analysers that have improved the lower limits of detection, precision and turnaround times. The ristocetin aggregation studies are useful in subtyping type 2B VWD. Genetic testing is required to confirm platelet type vs. type 2B VWD.

Keywords

von Willebrand disease VWF antigen Ristocetin cofactor assay 

References

  1. 1.
    Leebeek FW, Eikenboom JC. von Willebrand’s disease. N Engl J Med. 2016;375:2067–80.CrossRefGoogle Scholar
  2. 2.
    Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4:2103–14.CrossRefGoogle Scholar
  3. 3.
    Mancuso DJ, Tuley EA, Westfield LA, et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry. 1991;30:253–69.CrossRefGoogle Scholar
  4. 4.
    Adcock DM, Bethel M, Valcour A. Diagnosing von Willebrand disease: a large reference laboratory’s perspective. Semin Thromb Hemost. 2006;32:472–9.CrossRefGoogle Scholar
  5. 5.
    Federici AB. Current and emerging approaches for assessing von Willebrand disease in 2016. Int J Lab Hematol. 2016;38(Suppl 1):41–9.CrossRefGoogle Scholar
  6. 6.
    Federici AB, Budde U, Castaman G, et al. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost. 2013;39:191–201.CrossRefGoogle Scholar
  7. 7.
    Castaman G, Federici AB, Tosetto A, et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost. 2012;10:632–8.CrossRefGoogle Scholar
  8. 8.
    Castaman G, Goodeve A, Eikenboom J, et al. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013;98:667–74.CrossRefGoogle Scholar
  9. 9.
    Bowman ML, James PD. Bleeding scores for the diagnosis of von Willebrand disease. Semin Thromb Hemost. 2017;43:530–9.CrossRefGoogle Scholar
  10. 10.
    Castaman G, Linari S. Diagnosis and treatment of von Willebrand disease and rare bleeding disorders. J Clin Med. 2017;6. pii: E45.CrossRefGoogle Scholar
  11. 11.
    Hayward CP, Harrison P, Cattaneo M, et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006;4:312–9.CrossRefGoogle Scholar
  12. 12.
    Castaman G, Tosetto A, Cappelletti A, et al. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. Thromb Res. 2010;126:227–31.CrossRefGoogle Scholar
  13. 13.
    Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008;111:3540–5.CrossRefGoogle Scholar
  14. 14.
    Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood. 2003;101:2089–93.CrossRefGoogle Scholar
  15. 15.
    Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost. 2006;32:485–91.CrossRefGoogle Scholar
  16. 16.
    Kitchen S, Jennings I, Woods TA, et al. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for blood coagulation. Semin Thromb Hemost. 2006;32:492–8.CrossRefGoogle Scholar
  17. 17.
    Bodo I, Eikenboom J, Montgomery R, et al. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:1345–50.CrossRefGoogle Scholar
  18. 18.
    Flood VH, Gill JC, Morateck PA, et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman program for the molecular and clinical biology of VWD. Blood. 2011;117:e67–74.CrossRefGoogle Scholar
  19. 19.
    Favaloro EJ, Henniker A, Facey D, et al. Discrimination of von Willebrand’s disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems. Thromb Haemost. 2000;84:541–7.CrossRefGoogle Scholar
  20. 20.
    Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) expert panel report (USA). Haemophilia. 2008;14:171–232.CrossRefGoogle Scholar
  21. 21.
    Geisen U, Zieger B, Nakamura L, et al. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo. Thromb Res. 2014;134:246–50.CrossRefGoogle Scholar
  22. 22.
    Federici AB. Diagnosis of inherited von Willebrand disease: a clinical perspective. Semin Thromb Hemost. 2006;32:555–65.CrossRefGoogle Scholar
  23. 23.
    Mazurier C, Meyer D. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease—results of an international survey. On behalf of the subcommittee on von Willebrand factor of the scientific and standardization committee of the ISTH. Thromb Haemost. 1996;76:270–4.PubMedGoogle Scholar
  24. 24.
    Favaloro EJ, Mohammed S. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Thromb Res. 2016;141:202–11.CrossRefGoogle Scholar
  25. 25.
    Jousselme E, Jourdy Y, Rugeri L, et al. Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF. Int J Lab Hematol. 2018;40:77–83.CrossRefGoogle Scholar
  26. 26.
    Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost. 2010;104:1009–21.CrossRefGoogle Scholar
  27. 27.
    Flood VH, Schlauderaff AC, Haberichter SL, et al. Crucial role for the VWF A1 domain in binding to type IV collagen. Blood. 2015;125:2297–304.CrossRefGoogle Scholar
  28. 28.
    Flood VH, Gill JC, Christopherson PA, et al. Critical von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemost. 2012;10:1417–24.CrossRefGoogle Scholar
  29. 29.
    Favaloro EJ. Utility of the von Willebrand factor collagen binding assay in the diagnosis of von Willebrand disease. Am J Hematol. 2017;92:114–8.CrossRefGoogle Scholar
  30. 30.
    Flood VH, Gill JC, Friedman KD, et al. Collagen binding provides a sensitive screen for variant von Willebrand disease. Clin Chem. 2013;59:684–91.CrossRefGoogle Scholar
  31. 31.
    Budde U, Pieconka A, Will K, et al. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost. 2006;32:514–21.CrossRefGoogle Scholar
  32. 32.
    Ott HW, Griesmacher A, Schnapka-Koepf M, et al. Analysis of von Willebrand factor multimers by simultaneous high- and low-resolution vertical SDS-agarose gel electrophoresis and Cy5-labeled antibody high-sensitivity fluorescence detection. Am J Clin Pathol. 2010;133:322–30.CrossRefGoogle Scholar
  33. 33.
    Budde U, Schneppenheim R, Eikenboom J, et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost. 2008;6:762–71.CrossRefGoogle Scholar
  34. 34.
    Favaloro EJ, Facey D, Grispo L. Laboratory assessment of von Willebrand factor. Use of different assays can influence the diagnosis of von Willebrand’s disease, dependent on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms. Am J Clin Pathol. 1995;104:264–71.CrossRefGoogle Scholar
  35. 35.
    Frontroth JP, Hepner M, Sciuccati G, et al. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children. Thromb Haemost. 2010;104:1158–65.CrossRefGoogle Scholar
  36. 36.
    De Cuyper IM, Meinders M, van de Vijver E, et al. A novel flow cytometry-based platelet aggregation assay. Blood. 2013;121:e70–80.CrossRefGoogle Scholar
  37. 37.
    Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost. 2008;34:113–27.CrossRefGoogle Scholar
  38. 38.
    Veyradier A, Caron C, Ternisien C, et al. Validation of the first commercial ELISA for type 2N von Willebrand’s disease diagnosis. Haemophilia. 2011;17:944–51.CrossRefGoogle Scholar
  39. 39.
    Caron C, Mazurier C, Goudemand J. Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents. Br J Haematol. 2002;117:716–8.CrossRefGoogle Scholar
  40. 40.
    Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood. 2013;122:3735–40.CrossRefGoogle Scholar
  41. 41.
    Sanders YV, Groeneveld D, Meijer K, et al. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood. 2015;125:3006–13.CrossRefGoogle Scholar
  42. 42.
    Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood. 2006;108:3344–51.CrossRefGoogle Scholar
  43. 43.
    Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European study MCMDM-1VWD. Blood. 2008;111:3531–9.CrossRefGoogle Scholar
  44. 44.
    Casonato A, Cattini MG, Daidone V, et al. Diagnostic value of measuring platelet Von Willebrand factor in Von Willebrand disease. PLoS One. 2016;11:e0161310.CrossRefGoogle Scholar
  45. 45.
    Nair SC, Viswabandya A, Srivastava A. Diagnosis and management of von Willebrand disease: a developing country perspective. Semin Thromb Hemost. 2011;37:587–94.CrossRefGoogle Scholar
  46. 46.
    Baronciani L, Goodeve A, Peyvandi F. Molecular diagnosis of von Willebrand disease. Haemophilia. 2017;23:188–97.CrossRefGoogle Scholar
  47. 47.
    Tiede A, Rand JH, Budde U, et al. How I treat the acquired von Willebrand syndrome. Blood. 2011;117:6777–85.CrossRefGoogle Scholar
  48. 48.
    Siaka C, Rugeri L, Caron C, et al. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia. 2003;9:303–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Vishrut K. Srinivasan
    • 1
  • Jasmina Ahluwalia
    • 1
  1. 1.Department of HematologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations